Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
The New England Journal of Medicine
|
December 31, 2005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
, Beat Thürlimann, Aparna Keshaviah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
Michel Marty, Francesco Cognetti, Dominique Maraninchi, et al.
The Lancet. Oncology
|
October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Meredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Marco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
The Oncologist
|
July 31, 2010
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study
Jean-Marc Extra, Eric C Antoine, Anne Vincent-Salomon, et al.
The Lancet. Oncology
|
February 1, 2011
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
The Lancet. Oncology
|
November 21, 2007
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
The Lancet. Oncology
|
May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Diana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
British Journal of Cancer
|
July 15, 2015
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
Nathalie Quenel-Tueux, Marc Debled, Justine Rudewicz, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
The New England Journal of Medicine
|
December 31, 2005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
, Beat Thürlimann, Aparna Keshaviah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group
Michel Marty, Francesco Cognetti, Dominique Maraninchi, et al.
The Lancet. Oncology
|
October 25, 2011
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Meredith M Regan, Patrick Neven, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Marco Colleoni, Anita Giobbie-Hurder, Meredith M Regan, et al.
The Oncologist
|
July 31, 2010
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study
Jean-Marc Extra, Eric C Antoine, Anne Vincent-Salomon, et al.
The Lancet. Oncology
|
February 1, 2011
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
The Lancet. Oncology
|
November 21, 2007
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
Hervé Bonnefoi, Anil Potti, Mauro Delorenzi, et al.
The Lancet. Oncology
|
May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Diana Crivellari, Zhuoxin Sun, Alan S Coates, et al.
British Journal of Cancer
|
July 15, 2015
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer
Nathalie Quenel-Tueux, Marc Debled, Justine Rudewicz, et al.
Page
of 6